Evidence map›Paper›PMID 41032140›Full record

ArticleJournal of molecular neuroscience : MN2025

Higher Serum Aspartate May be Associated with Better Cognitive Function as Mediated by Reduced Aβ Accumulation in Frontal and Temporal Lobes in Mild Cognitive Impairment.

Sarraa Ahmad Qahtan, Ali Fawzi Al-Hussainy, Vimal Arora, M M Rekha, Mayank Kundlas, Kattela Chennakesavulu, Mehul Manu, Jasur Rizaev, Sada Ghalib Taher, Mariem Alwan and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarraa Ahmad QahtanDepartment of Anesthesia Techniques, Health and Medical Techniques College, Alnoor University, Mosul, Iraq. sarraa.ahmad@alnoor.edu.iq.
Ali Fawzi Al-HussainyCollege of Pharmacy, Ahl Al Bayt University, Kerbala, Iraq.
Vimal AroraUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
M M RekhaDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Mayank KundlasCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Kattela ChennakesavuluDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Mehul ManuDepartment of Allied Science (Physics), Graphic Era Hill University, Bhimtal, India.
Jasur RizaevDepartment of Public Health and Healthcare Management, Samarkand State Medical University, 18, Amir Temur Street, Samarkand,, Rector, Uzbekistan.
Sada Ghalib TaherCollege of Dentistry, University of Thi-Qar, Thi-Qar-64001, Nasiriyah, Iraq.
Mariem AlwanPharmacy College, Al-Farahidi University, Baghdad, Iraq.
Mahmood JawadDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Hiba MushtaqGilgamesh Ahliya University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspartate, a key excitatory neurotransmitter, has shown conflicting links to cognitive disorders like Alzheimer's disease (AD) and mild cognitive impairment (MCI). Given its role in brain function, studying its relationship with amyloid-beta (Aβ) accumulation may provide important insights into these conditions. This study is the first to examine the link between serum aspartate levels, Aβ accumulation in key brain regions, and cognitive function (via ADAS-Cog) across cognitively normal (n = 113), MCI (n = 283), and AD (n = 24) participants. The results showed significant increases in Aβ accumulation across all brain regions from CN to MCI and AD groups (overall p < 0.001; pairwise p ≤ 0.001). In individuals with MCI, elevated aspartate levels were inversely associated with Aβ accumulation in the frontal (β = - 0.122, p = 0.041) and temporal regions (β = - 0.128, p = 0.032), but this relationship was lost after adjusting for age, gender, education, handedness, and ApoE ɛ4, ɛ3, and ɛ2 genotypes. Further analysis identified age and ApoE ɛ4, ɛ3 status as key modifiers of the aspartate-Aβ relationship in MCI. Mediation analysis revealed that higher serum aspartate levels were associated with better cognitive function, potentially mediated by reduced Aβ accumulation in the frontal (β = - 0.037) and temporal lobes (β = - 0.043) in MCI, but this effect disappeared after adjusting for demographic factors and ApoE genotypes. Overall, higher serum aspartate levels may be associated with reduced Aβ accumulation and improved cognitive outcomes in MCI, with age and ApoE genotypes acting as key confounders.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAspartic AcidCognitionCognitive DysfunctionFrontal LobeTemporal LobeAgedAged, 80 and overApolipoproteins EFemaleHumansMaleMiddle AgedAmyloid beta-PeptidesApolipoproteins EAspartic AcidAlzheimer’s diseaseAmyloid-beta (Aβ)AspartateAβ accumulationBrain functionCognitive impairment

Identifiers

PMID41032140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.